Opioid Dependence News and Research

RSS

Opioid abuse and dependence diagnoses found among all age group in urban, rural settings

In rural areas around the country, in the period 2007 to 2016, private insurance claim lines with opioid abuse and dependence diagnoses were found in every age group from 13- 18 years to over 80 years, and in urban areas, in every age group from 13-18 years to 71-80 years.

13 Jun 2017

Medical responses to opioid addiction vary by state, analysis finds

Location, location, location. That mantra may apply even when it comes to how opioid addiction is treated.

12 Jun 2017

Opioid use gradually increases few years after bariatric surgery, study shows

While the proportion of adults with severe obesity using prescription opioids initially declines in the months after bariatric surgery, it increases within a matter of years, eventually surpassing pre-surgery rates of patients using the potentially addictive pain medications, according to new research from a National Institutes of Health -funded multicenter study led by the University of Pittsburgh Graduate School of Public Health.

6 Jun 2017

Study finds opioid dependence and overdose rates after urologic surgery

About 1 in 1,111 patients who undergo urologic surgery for conditions such as prostate cancer and kidney stones experience opioid dependence or overdose (ODO), a Loyola Medicine study has found.

30 May 2017

Study finds depression and SUD to be strongest risk factors for prescription opioid overdose

Individuals suffering from a substance use disorder (SUD) or depression are among those at highest risk for a serious prescription opioid overdose, according to a study published in Pain Medicine.

13 Apr 2017

Study reveals that 25% of women with prenatal opioid addiction are not being treated

A new study by Queen's University researcher Susan Brogly (Surgery) has revealed that 25 per cent of women suffering from a prenatal opioid dependence were not being treated for their addiction.

5 Apr 2017

CRNAs urge patients to learn about risks, benefits of pain relief treatments

The opioid crisis is one of the largest challenges facing today's healthcare professionals and the patients for whom they care.

8 Mar 2017

SCS therapy can be key to reducing use of opioids in patients battling chronic pain, study finds

New research has found spinal cord stimulation (SCS) therapy can be key to reducing or stabilizing the use of opioids in patients battling chronic pain.

20 Jan 2017

Study identifies factors linked to disengagement from treatment for opioid use disorder

Individuals with opioid use disorder who are treated with buprenorphine, a commonly prescribed drug to treat addiction, are more likely to disengage from treatment programs if they are black or Hispanic, unemployed, or have hepatitis C according to a study published online in the Journal of Substance Abuse Treatment.

5 Jan 2017

Opioid users treated in compulsory drug detention centre more likely to relapse, study shows

People with chronic opioid use disorders are more likely to relapse and do so sooner if they are treated in a compulsory drug detention centre rather than a voluntary drug treatment centre using methadone maintenance therapy, according to the first study comparing the outcome of both approaches published in The Lancet Global Health.

9 Dec 2016

New study finds opioid dependence affects perception of cute images of babies

A new pilot study has found that opioid dependence - which includes dependence on drugs such as heroin - affects how 'cute' we perceive images of children to be.

19 Sep 2016

Buprenorphine implants could be effective option to treat adults with opioid dependence

While buprenorphine has long been used to treat adults with opioid dependence, its efficacy can be hindered by lack of adherence to daily, sublingual (beneath the tongue) doses of the medication.

19 Jul 2016

Study identifies persistent opioid use in some patients after knee or hip replacement

Many patients undergoing hip or knee replacement are still taking prescription opioid pain medications up to six months after surgery, reports a study in PAIN, the official publication of the International Association for the Study of Pain.

1 Jun 2016

First buprenorphine implant for opioid dependence treatment gets FDA approval

The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.

27 May 2016

Naltrexone injections could reduce risk of relapse among opioid dependent individuals

In a multicenter, randomized clinical trial, ex-prisoners who received six monthly injections of naltrexone--a long-acting medication that blocks opioid receptors in the brain--were significantly less likely to resume opioid use than those who received counseling and referrals to community treatment centers without naltrexone.

31 Mar 2016

First patient enrolled in Phase 3 efficacy trial of CAM2038 for opioid dependence

Braeburn Pharmaceuticals and Camurus announce that the first patient has been randomized in the double blind Phase 3 efficacy trial of CAM2038 in opioid-dependent patients. CAM2038 medications are designed for long-acting weekly and monthly administration.

31 Dec 2015

Women need different treatment from men with addiction, says McMaster University-led study

Painkillers prescribed by doctors are the starting point for an opioid addiction for more than half of female methadone clinic patients, and they need different treatment from men with addiction, says a study led by McMaster University researchers.

10 Nov 2015

Braeburn, Camurus announce FDA Fast Track designation for CAM2038 to treat opioid addiction

Braeburn Pharmaceuticals and Camurus announced today that the U.S. Food and Drug Administration granted Fast Track designation for the CAM2038 weekly and monthly buprenorphine subcutaneous injection products under development for the treatment of opioid addiction.

5 Nov 2015

BDSI announces FDA approval of BUNAVAIL sNDA for manufacturing specification change

BioDelivery Sciences International, Inc. announced that the U.S. Food and Drug Administration has approved the company's Supplemental New Drug Application (sNDA) for a manufacturing specification change for BUNAVAIL (buprenorphine and naloxone) buccal film (CIII).

15 Oct 2015

FDA accepts Braeburn's resubmission of Probuphine NDA for review

Braeburn Pharmaceuticals, an Apple Tree Partners company, today announced that the U.S. Food and Drug Administration has accepted Braeburn's resubmission of the Probuphine New Drug Application (NDA) for review and set February 27, 2016 as the target date for Agency action.

28 Sep 2015